Continuous administration trial of Phase2 Study of OCV-101 in Combination With Gemcitabine in Patients With Unresectable Advanced Pancreatic Cancer and Recurrent Pancreatic Cancer
Not Applicable
- Conditions
- nresectable Advanced and Recurrent Pancreatic cancer
- Registration Number
- JPRN-UMIN000009085
- Lead Sponsor
- OncoTherapy Science, Inc.
- Brief Summary
Not available
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- Complete: follow-up complete
- Sex
- All
- Target Recruitment
- 2
Inclusion Criteria
Not provided
Exclusion Criteria
Not provided
Study & Design
- Study Type
- Interventional
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method Overall Survival (OS)
- Secondary Outcome Measures
Name Time Method